The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Efficacy of a new once-daily long-acting inhaled 2-agonist indacaterol versus twice-daily formoterol in COPD
Open accessAbstract
BACKGROUND: Indacaterol is a long-acting inhaled beta(2)-agonist (LABA) for the treatment of chronic obstructive pulmonary disease (COPD). In previous studies, indacaterol provided 24 h bronchodilation on once-daily dosing with a fast onset of action. This study compared the efficacy and safety of indacaterol with the twice-daily LABA formoterol and placebo over 1 year. METHODS: Patients with moderate to severe COPD were randomised to receive once-daily indacaterol 300 microg (n=437) or 600 microg (n=428), twice-daily formoterol 12 microg (n=435) or placebo (n=432) for 52 weeks in a double-blind double-dummy parallel group study. The primary efficacy variable was forced expiratory volume in 1 s (FEV(1)) measured 24 h postdose after 12 weeks (indacaterol vs placebo). Other outcomes included dyspnoea (transition dyspnoea index, TDI), use of as-needed salbutamol, symptom-based measures recorded on diary cards, exacerbations, health status (St George's Respiratory Questionnaire), BODE index (body mass index, obstruction, dyspnoea, exercise), safety and tolerability. RESULTS: Indacaterol increased 24 h postdose FEV(1) after 12 weeks by 170 ml (both doses) versus placebo and by 100 ml versus formoterol (all p<0.001). These significant differences were maintained at 52 weeks. Symptomatic outcomes were improved compared with placebo with all active treatments, and indacaterol was more effective than formoterol in improving TDI score and reducing the need for as-needed salbutamol. Indacaterol was well tolerated and had a good overall safety profile, including minimal impact on QTc interval and systemic beta(2)-mediated events. CONCLUSIONS: Once-daily indacaterol is an effective 24 h bronchodilator that improves symptoms and health status and confers clinical improvements over a twice-daily 12 h LABA as a treatment for patients with moderate to severe COPD. TRIAL REGISTRATION NUMBER: NCT 00393458.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vestbo, J., Hurd, S. S., Agustí, A. G., Jones, P. W., Vogelmeier, C., Anzueto, A., Barnes, P. J., Fabbri, L. M., Martinez, F. J., Nishimura, M., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201204-0596pp · Cited by 15,983
ATS Statement: Guidelines for the Six-Minute Walk Test
(2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.166.1.at1102 · Cited by 11,195
Rabe, K. F., Hurd, S., Anzueto, A., Barnes, P. J., Buist, S. A., Calverley, P., Fukuchi, Y., Jenkins, C., Rodriguez-Roisin, R., van Weel, C., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-456so · Cited by 4,925
Celli, B. R., Cote, C. G., Marin, J. M., Casanova, C., Montes de Oca, M., Mendez, R. A., Pinto Plata, V., & Cabral, H. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa021322 · Cited by 4,015
Global Initiative for Chronic Obstructive Lung Disease (GOLD)
Rahman, M. M., & Siddiqui, M. M. R. (2017) · Anwer Khan Modern Medical College Journal · doi:10.3329/akmmcj.v7i1.31596 · Cited by 3,106
Jones, P. W., Quirk, F. H., Baveystock, C. M., & Littlejohns, P. (1992) · American Review of Respiratory Disease · doi:10.1164/ajrccm/145.6.1321 · Cited by 3,035
Bestall, J. C., Paul, E. A., Garrod, R., Garnham, R., Jones, P. W., & Wedzicha, J. A. (1999) · Thorax · doi:10.1136/thx.54.7.581 · Cited by 2,927
The St George's Respiratory Questionnaire
Jones, P. W., Quirk, F. H., & Baveystock, C. M. (1991) · Respiratory Medicine · doi:10.1016/s0954-6111(06)80166-6 · Cited by 2,683
Evaluation of Clinical Methods for Rating Dyspnea
Mahler, D. A., & Wells, C. K. (1988) · Chest · doi:10.1378/chest.93.3.580 · Cited by 1,822
Mahler, D. A., Weinberg, D. H., Wells, C. K., & Feinstein, A. R. (1984) · Chest · doi:10.1378/chest.85.6.751 · Cited by 1,292
Outcomes for COPD pharmacological trials: from lung function to biomarkers
Cazzola, M., MacNee, W., Martinez, F. J., Rabe, K. F., Franciosi, L. G., Barnes, P. J., Brusasco, V., Burge, P. S., Calverley, P. M. A., Celli, B. R., et al. (2008) · European Respiratory Journal · doi:10.1183/09031936.00099306 · Cited by 858
St. George's Respiratory Questionnaire: MCID
Jones, P. W. (2005) · COPD: Journal of Chronic Obstructive Pulmonary Disease · doi:10.1081/copd-200050513 · Cited by 855
Wedzicha, J. A., Calverley, P. M. A., Seemungal, T. A., Hagan, G., Ansari, Z., & Stockley, R. A. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200707-973oc · Cited by 827
Guidelines for the six-minute walk test
Ats, S. (2002) · Medical Entomology and Zoology · Cited by 651
Bourbeau, J., & Bartlett, S. J. (2008) · Thorax · doi:10.1136/thx.2007.086041 · Cited by 490 · cited 1×
“reversibility of 17%. Nevertheless, the present double-blind comparison shows that indacaterol is the more effective bronchodilator and is similar or more effective for clinical outcomes. In addition, patient adherence to a once-daily dosing regimen may be better than with a twice-daily regimen since frequency of dosi…”
BackgroundPizov, R. (2004) · Survey of Anesthesiology · doi:10.1097/01.sa.0000144225.72154.cf · Cited by 392
Inhaled Formoterol Dry Powder Versus Ipratropium Bromide in Chronic Obstructive Pulmonary Disease
DAHL, R., GREEFHORST, L. A. P. M., NOWAK, D., NONIKOV, V., BYRNE, A. M., THOMSON, M. H., TILL, D., & DELLA CIOPPA, G. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.164.5.2007006 · Cited by 358
Self-citationRossi, A., Kristufek, P., Levine, B. E., Thomson, M. H., Till, D., Kottakis, J., & Della Cioppa, G. (2002) · Chest · doi:10.1378/chest.121.4.1058 · Cited by 250
Minimal important difference of the transition dyspnoea index in a multinational clinical trial
Witek, T. J., & Mahler, D. A. (2003) · European Respiratory Journal · doi:10.1183/09031936.03.00068503a · Cited by 226
Partridge, M. R., Karlsson, N., & Small, I. R. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990903103006 · Cited by 186
The MCID of the Transition Dyspnea Index is a Total Score of One Unit
Mahler, D. A., & Witek, T. J. (2005) · COPD: Journal of Chronic Obstructive Pulmonary Disease · doi:10.1081/copd-200050666 · Cited by 181
Prediction of risk of COPD exacerbations by the BODE index
Marín, J. M., Carrizo, S. J., Casanova, C., Martínez‐Camblor, P., Soriano, J. B., Agustí, A. G. N., & Celli, B. R. (2008) · Respiratory Medicine · doi:10.1016/j.rmed.2008.10.004 · Cited by 147
Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design
Barnes, P. J., Pocock, S., MAGNUSSEN, H., Iqbal, A., Krämer, B., Higgins, M., & Lawrence, D. (2010) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2010.01.003 · Cited by 116
Self-citationA dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison
Rennard, S. I., Bantje, T. A., Centanni, S., Chanez, P., Чучалин, А. Г., D’Urzo, A. D., Kornmann, O., Perry, S., Jack, D., Owen, R. J., et al. (2008) · Respiratory Medicine · doi:10.1016/j.rmed.2008.02.001 · Cited by 89
Self-citationBauwens, O., Ninane, V., de Maele, B. V., Firth, R., Dong, F., Owen, R. J., & Higgins, M. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802675096 · Cited by 46
Self-citationDonohue, J. F., Hanania, N. A., Sciarappa, K., Goodwin, E., Grogan, D. R., Baumgartner, R. A., & Hanrahan, J. P. (2008) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465808089455 · Cited by 33
Cited by
Tiotropium versus Salmeterol for the Prevention of Exacerbations of COPD
Vogelmeier, C., Hederer, B., Glaab, T., Schmidt, H., Rutten-van Mölken, M. P. M. H., Beeh, K. M., Rabe, K. F., & Fabbri, L. M. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1008378 · Cited by 684
Wedzicha, J. A., Decramer, M., Ficker, J. H., Niewoehner, D. E., Sandström, T., Taylor, A. F., D'Andrea, P., Arrasate, C., Chen, H., & Banerji, D. (2013) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(13)70052-3 · Cited by 535
Pharmacology and Therapeutics of Bronchodilators
Cazzola, M., Page, C. P., Calzetta, L., & Matera, M. G. (2012) · Pharmacological Reviews · doi:10.1124/pr.111.004580 · Cited by 467
Cardiovascular disease and COPD: dangerous liaisons?
Rabe, K. F., Hurst, J. R., & Suissa, S. (2018) · European Respiratory Review · doi:10.1183/16000617.0057-2018 · Cited by 410
Longitudinal Changes in Patient-reported Dyspnea in Patients with COPD
Mahler, D. A., Ward, J., Waterman, L. A., & Baird, J. C. (2012) · COPD: Journal of Chronic Obstructive Pulmonary Disease · doi:10.3109/15412555.2012.701678 · Cited by 27
Metadata
- Authors
- Dahl, R., Chung, K. F., Buhl, R., Magnussen, H., Nonikov, V., Jack, D., Bleasdale, P., Owen, R., Higgins, M., Kramer, B., & on behalf of the INVOLVE (INdacaterol: Value in COPD: Longer Term Validation of Efficacy and Safety) Study Investigators
- Venue
- Thorax
- Publisher
- BMJ
- Published
- 2010-06-01
- Volume
- 65
- Issue
- 6
- Pages
- 473-479
- ISSN
- 0040-6376 (ISSN-L)
- OpenAlex
- W2117079401
- Cited by
- 273
- References
- 26
- FWCI
- 35.91
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.